eligibility_summary
Age ≥18 with recurrent/metastatic HNSCC or other solid tumor after standard therapy, measurable lesion (RECIST 1.1), provide tumor/blood, ECOG 0–1, life ≥12wks, contraception, nonpregnant, consent. Exclude: prior B7‑H3, recent therapy/RT/surgery, CNS disease, effusions, CYP3A4/QT‑risk meds, >G2 toxicities, organ/CV dysfunction, uncontrolled diabetes, recent bleeding/thrombosis/infection, immunosuppression, HBV/HCV/TB/syphilis/HIV, serious pulmonary or neuro/psych disease, HS‑20093 allergy.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: ARTEMIS-006 (Phase 2, single-arm) tests HS-20093, an intravenous, fully humanized IgG1 antibody–drug conjugate (ADC). Mechanism: HS-20093 binds B7-H3 (CD276), a B7-family immune co-signaling molecule broadly overexpressed on solid tumor cells, is internalized, and releases a cytotoxic payload to kill B7-H3–positive cells. Indication: recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) and other advanced solid tumors after standard therapy failure. Targeted cells/pathways: tumor cells with high B7-H3 expression (and potentially B7-H3 in the tumor microenvironment), leveraging B7-H3–mediated tumor-selective delivery, downstream effect is direct cytotoxicity of B7-H3–expressing cancer cells. Dose: 10 mg/kg monotherapy. Outcome focus: efficacy, safety, PK, immunogenicity.